Table 2.

Most frequent TEAEs related to study treatment by maximum CTCAE grade categories

Adverse events	Crenigacestat 25 mg (n = 4)			Crenigacestat 50 mg (n = 7)
	Grade 1	Grade 2	Grade 3	Grade 1	Grade 2	Grade 3
Gastrointestinal disorders	2 (50.0)	0	0	1 (14.3)	2 (28.6)	0
Diarrhoea	1 (25.0)	0	0	2 (28.6)	0	0
Vomiting	1 (25.0)	0	0	1 (14.3)	0	0
Nausea	0	0	0	1 (14.3)	2 (28.6)	0
Malaise	1 (25.0)	0	0	1 (14.3)	0	0
Metabolism and nutrition disorders	0	0	0	0	2 (28.6)	2 (28.6)
Decreased appetite	0	0	0	1 (14.3)	2 (28.6)	0
Hypophosphataemia	0	0	0	0	0	2 (28.6)
Hepatic enzyme increased	0	0	1 (25.0)	0	0	0
Eye disorders	1 (25.0)	0	0	0	0	0
Visual impairment	1 (25.0)	0	0	0	0	0
Skin and subcutaneous tissue disorders	0	0	0	2 (28.6)	0	0
Rash	0	0	0	1 (14.3)	0	0
Alopecia	0	0	0	1 (14.3)	0	0
Hair color changes	0	0	0	1 (14.3)	0	0

Data reported as n (%). Adverse events were coded using MedDRA terms (Version 22.0)

Abbreviations: CTCAE Common Terminology Criteria for Adverse Events, MedDRA Medical Dictionary for Regulatory Activites, n number of patients